We describe a patient presenting for evaluation of nearly annual pneumonias since the age of 9 years, eventually requiring multiple hospitalizations. Genetic testing revealed compound heterozygous mutations for 2184insA and L206W, indicative of cystic fibrosis. The patient received Trikafta (combination of ivacaftor, tezacaftor, and elexacaftor), a cystic fibrosis transmembrane regulator modulator with subsequent improvement of her symptoms. This case highlights the importance of maintaining a broad differential diagnosis for recurrent pulmonary infections, including diagnoses not typical for a patient's population or age group. Initiation of therapies such as Trikafta has been associated with improvement in lung function in a life-limiting disease.
Elsabagh et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: